The following table presents the amounts of share-based compensation expense recognized in LivaNova’s condensed consolidated statements of income (loss) by type of arrangement (in thousands):


	Three Months Ended March 31,
		2026		2025
Service-based RSUs		$	4,438	$	3,548
Service-based SARs		3,085		2,753
Market performance-based RSUs		168		414
Operating performance-based RSUs		226		821
Employee share purchase plan		353		247
		$	8,270	$	7,783

Share-based compensation granted for the three months ended March 31, 2026, representing potential shares and their weighted average grant date fair values by type, is as follows (shares in thousands, fair value in dollars):


	Three Months Ended March 31, 2026
	Shares	Weighted Average Grant Date Fair Value
Service-based RSUs	533	$	61.27
Performance-based RSUs (1) (2)	188	70.26

(1)Awards cliff vest after three years and are subject to performance conditions, including the rank of LivaNova’s total shareholder return for the three-year period ending December 31, 2028 relative to the total shareholder returns of the S&P Healthcare Equipment Select Constituents index, as well as the achievement of specified cumulative revenue growth and adjusted EPS performance thresholds.

(2)Represents shares based on an assumed 100% performance achievement. Performance-based RSU awards have a minimum and maximum possible achievement level of 0% and 200%, respectively.